GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » Net Current Asset Value

CardioGenics Holdings (CardioGenics Holdings) Net Current Asset Value : $-0.02 (As of Jan. 2016)


View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

CardioGenics Holdings's net current asset value per share for the quarter that ended in Jan. 2016 was $-0.02.

The historical rank and industry rank for CardioGenics Holdings's Net Current Asset Value or its related term are showing as below:

CGNH's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.19
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

CardioGenics Holdings Net Current Asset Value Historical Data

The historical data trend for CardioGenics Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings Net Current Asset Value Chart

CardioGenics Holdings Annual Data
Trend Jul06 Jul07 Jul08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 -0.01 -0.02 -0.03 -0.02

CardioGenics Holdings Quarterly Data
Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Jul15 Oct15 Jan16
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.02 -0.02

Competitive Comparison of CardioGenics Holdings's Net Current Asset Value

For the Diagnostics & Research subindustry, CardioGenics Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CardioGenics Holdings's Price-to-Net-Current-Asset-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CardioGenics Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where CardioGenics Holdings's Price-to-Net-Current-Asset-Value falls into.



CardioGenics Holdings Net Current Asset Value Calculation

CardioGenics Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Oct. 2015 is calculated as

Net Current Asset Value Per Share(A: Oct. 2015 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.052-1.795-0-0)/92.214
=-0.02

CardioGenics Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Jan. 2016 is calculated as

Net Current Asset Value Per Share(Q: Jan. 2016 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.385-2.345-0-0)/92.8667
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CardioGenics Holdings  (OTCPK:CGNH) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


CardioGenics Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CardioGenics Holdings (CardioGenics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8
CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines